376 related articles for article (PubMed ID: 19523876)
21. Cystine-knot peptides: emerging tools for cancer imaging and therapy.
Ackerman SE; Currier NV; Bergen JM; Cochran JR
Expert Rev Proteomics; 2014 Oct; 11(5):561-72. PubMed ID: 25163524
[TBL] [Abstract][Full Text] [Related]
22. NMR as a tool for elucidating the structures of circular and knotted proteins.
Craik DJ; Daly NL
Mol Biosyst; 2007 Apr; 3(4):257-65. PubMed ID: 17372654
[TBL] [Abstract][Full Text] [Related]
23. Novel miniproteins engineered by the transfer of active sites to small natural scaffolds.
Vita C; Vizzavona J; Drakopoulou E; Zinn-Justin S; Gilquin B; Ménez A
Biopolymers; 1998; 47(1):93-100. PubMed ID: 9692330
[TBL] [Abstract][Full Text] [Related]
24. Conformation and mode of membrane interaction in cyclotides. Spatial structure of kalata B1 bound to a dodecylphosphocholine micelle.
Shenkarev ZO; Nadezhdin KD; Sobol VA; Sobol AG; Skjeldal L; Arseniev AS
FEBS J; 2006 Jun; 273(12):2658-72. PubMed ID: 16817894
[TBL] [Abstract][Full Text] [Related]
25. Cystine-knot peptides targeting cancer-relevant human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
Maaß F; Wüstehube-Lausch J; Dickgießer S; Valldorf B; Reinwarth M; Schmoldt HU; Daneschdar M; Avrutina O; Sahin U; Kolmar H
J Pept Sci; 2015 Aug; 21(8):651-60. PubMed ID: 25964162
[TBL] [Abstract][Full Text] [Related]
26. Oxidative folding of peptides with cystine-knot architectures: kinetic studies and optimization of folding conditions.
Reinwarth M; Glotzbach B; Tomaszowski M; Fabritz S; Avrutina O; Kolmar H
Chembiochem; 2013 Jan; 14(1):137-46. PubMed ID: 23229141
[TBL] [Abstract][Full Text] [Related]
27. Cyclotides: a patent review.
Smith AB; Daly NL; Craik DJ
Expert Opin Ther Pat; 2011 Nov; 21(11):1657-72. PubMed ID: 22017409
[TBL] [Abstract][Full Text] [Related]
28. Chemical synthesis, backbone cyclization and oxidative folding of cystine-knot peptides: promising scaffolds for applications in drug design.
Reinwarth M; Nasu D; Kolmar H; Avrutina O
Molecules; 2012 Oct; 17(11):12533-52. PubMed ID: 23095896
[TBL] [Abstract][Full Text] [Related]
29. Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides.
Gunasekera S; Foley FM; Clark RJ; Sando L; Fabri LJ; Craik DJ; Daly NL
J Med Chem; 2008 Dec; 51(24):7697-704. PubMed ID: 19053834
[TBL] [Abstract][Full Text] [Related]
30. Protease-resistant peptide ligands from a knottin scaffold library.
Getz JA; Rice JJ; Daugherty PS
ACS Chem Biol; 2011 Aug; 6(8):837-44. PubMed ID: 21615106
[TBL] [Abstract][Full Text] [Related]
31. Cycloviolacin H4, a hydrophobic cyclotide from Viola hederaceae.
Chen B; Colgrave ML; Wang C; Craik DJ
J Nat Prod; 2006 Jan; 69(1):23-8. PubMed ID: 16441062
[TBL] [Abstract][Full Text] [Related]
32. Isolation, characterization, and bioactivity of cyclotides from the Micronesian plant Psychotria leptothyrsa.
Gerlach SL; Burman R; Bohlin L; Mondal D; Göransson U
J Nat Prod; 2010 Jul; 73(7):1207-13. PubMed ID: 20575512
[TBL] [Abstract][Full Text] [Related]
33. Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles.
Kintzing JR; Cochran JR
Curr Opin Chem Biol; 2016 Oct; 34():143-150. PubMed ID: 27642714
[TBL] [Abstract][Full Text] [Related]
34. Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery.
Gould A; Ji Y; Aboye TL; Camarero JA
Curr Pharm Des; 2011 Dec; 17(38):4294-307. PubMed ID: 22204428
[TBL] [Abstract][Full Text] [Related]
35. Structural plasticity of the cyclic-cystine-knot framework: implications for biological activity and drug design.
Clark RJ; Daly NL; Craik DJ
Biochem J; 2006 Feb; 394(Pt 1):85-93. PubMed ID: 16300479
[TBL] [Abstract][Full Text] [Related]
36. Amino acid requirement for the high affinity binding of a selected arginine-rich peptide with the HIV Rev-response element RNA.
Sugaya M; Nishino N; Katoh A; Harada K
J Pept Sci; 2008 Aug; 14(8):924-35. PubMed ID: 18351707
[TBL] [Abstract][Full Text] [Related]
37. Discovery and applications of the plant cyclotides.
Craik DJ
Toxicon; 2010 Dec; 56(7):1092-102. PubMed ID: 20219513
[TBL] [Abstract][Full Text] [Related]
38. Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration.
Werle M; Kafedjiiski K; Kolmar H; Bernkop-Schnürch A
Int J Pharm; 2007 Mar; 332(1-2):72-9. PubMed ID: 17070661
[TBL] [Abstract][Full Text] [Related]
39. Backbone cyclization of a recombinant cystine-knot peptide by engineered Sortase A.
Stanger K; Maurer T; Kaluarachchi H; Coons M; Franke Y; Hannoush RN
FEBS Lett; 2014 Nov; 588(23):4487-96. PubMed ID: 25448598
[TBL] [Abstract][Full Text] [Related]
40. Fragmentation follows structure: top-down mass spectrometry elucidates the topology of engineered cystine-knot miniproteins.
Reinwarth M; Avrutina O; Fabritz S; Kolmar H
PLoS One; 2014; 9(10):e108626. PubMed ID: 25303319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
